Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of Ciclosporin for Atopic Dermatitis
NCT00232063Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2004
- Primary completion
- Nov 2005
- Modality
- Peptides, Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of cyclosporine microemulsion in atopic dermatitis (AD), sponsored by Novartis. Primary endpoint: Safety and Efficacy at 52 weeks. Started May 2004; status: completed.
02
Drugs
cyclosporine microemulsion
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00232063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232063.